Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of &quot;normal&quot; residual plasma cell analysis by Pojero, F. et al.
Original Article
Old and New Immunophenotypic Markers in
Multiple Myeloma for Discrimination of
Responding and Relapsing Patients: The Impor-
tance of “Normal” Residual Plasma Cell Analysis
Fanny Pojero,1,2†* Alessandra Casuccio,3† Maria Francesca Parrino,1
Giovanni Cardinale,4 Giuseppina Colonna Romano,2 Calogero Caruso,2
and Francesco Gervasi1
1D.S.O.U. Specialistic Laboratory Oncology, Hematology and Cell Cultures for Clinical Use, ARNAS Civico,
Piazza Nicola Leotta 4, Palermo 90127, Italy
2Department of Pathobiology and Medical and Forensic Biotechnologies, University of Palermo,
Corso Tukory 211, Palermo 90134, Italy
3Department of Sciences for Health Promotion and Mother-Child Care, University of Palermo,
Via del Vespro 133, Palermo 90133, Italy
4C.O.U. of Onco-Hematology, ARNAS Civico, Piazza Nicola Leotta 4, Palermo 90127, Italy
Background: Multiple myeloma is an incurable disease characterized by proliferation of clonal malignant
plasma cells (CPCs), which can be immunophenotypically distinguished from polyclonal plasma cells
(PPCs) by multiparameter flow cytometry (MFC). The utility of PPCs analysis in detecting prognostic and pre-
dictive information is still a matter of debate. Methods: we tested the ability of 11 MFC markers in detecting
differences in the immunophenotype of CPCs and PPCs among patients in various disease stages; we veri-
fied if these markers could be associated with disease stage/response to therapy despite the role of clinical
parameters. Results: significant changes in the expression of markers occurred both in CPCs and PPCs.
CD58 on PPCs of responding patients was downregulated compared with PPC of relapsing group. Fraction of
CD200 expressing PCs was lower in control subjects than in PPCs from MGUS and myeloma groups. CD11a
levels of expression on both CPCs and PPCs showed an upregulation in newly diagnosed and relapsing
patients versus PCs of controls; CD20 was less expressed on control PCs than on MGUS CPCs and PPCs.
CD49d revealed to be advantageous in discrimination of PPCs from CPCs. In our multiple regression model,
CD19 and CD49d on CPCs, and CD45, CD58 and CD56 on PPCs maintained their association with groups of
patients independently of other prognostic variables. Conclusions: we provide a feasible start point to put in
order ranges of expression on PPCs in healthy and myeloma subjects; we propose a new approach based
on PPC analysis to monitor the stages of the disease. VC 2014 International Clinical Cytometry Society
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Multiple myeloma (MM) is an incurable neoplastic
plasma cell (PC) disorder characterized by proliferation
of clonal malignant plasma cells (CPCs) in bone marrow
(BM), and presence of monoclonal protein (M protein)
in blood and/or urine, associated with organ dysfunction
(1). The first stage in the development of MM is the
emergence of asymptomatic monoclonal gammopathy of
undetermined significance (MGUS). In some of these
patients, this progresses to smoldering MM and ulti-
mately to symptomatic MM, with an annual risk of
around 1% for patients with MGUS (2). MM accounts for
approximately 1% diseases and is the second most com-
mon hematologic cancer. The incidence of MM in
Europe is 4.5–6.0/100,000/year with a median age at
diagnosis of between 63 and 70 years; the mortality is
4.1/100,000/year (3). Treatment differs among autolo-
gous stem cell transplantation eligible patients and those
who are not candidates (4); responsiveness to treat-
ments varies largely among patients due to the high het-
erogeneity of MM. The decision of which treatment is
best has been a difficult issue in MM. However, due to
the introduction of novel drugs (bortezomib, lenalido-
mide and thalidomide) that have been able to achieve
good quality responses, changes in treatment strategies
can be seen (5). The importance of reaching complete
response (CR) is undoubtedly recognized in the trans-
plant setting (6–8) although it is less clear in the non-
trasplant setting. Clinicians may benefit from multipara-
meter flow cytometry (MFC), since this technology
allows to define the immunophenotypic characteristics
of CPCs, to study normal/reactive polyclonal PCs (PPCs)
of both healthy and MM subjects, to distinguish CPCs
from PPC pool (9–14), to evaluate the risk of progres-
sion from MGUS to MM (15,16) and the presence of
minimal residual disease (MRD) (10,17,18), to identify
new therapeutic targets (19–21), and to provide prog-
nostic information. For some markers, immunopheno-
typic appropriateness and prognostic role have already
been explored (CD27, CD56, CD117, CD19, CD45)
(22–25), instead other markers have been less investi-
gated (CD20 and CD200) (12,22,26,27) or their utility is
still a matter of debate (CD30, CD49d, CD11a and
CD58) (28–36). MFC data flank other factors influencing
prognosis such as ISS and Durie-Salmon stage at diagno-
sis, hyper- and hypodiploidy and lactate dehydrogenase
levels (37–39). A commonly described experimental
approach is based on the study of immunophenotype of
CPCs (and sometimes residual PPCs), dividing patients
in newly diagnosed subjects and treated/relapsed
patients. It is not fully demonstrated if PPCs in BM post
therapies may exhibit immunophenotypic variations
interfering with MRD detection; similarly it is not clear
if disease progression or response to therapy may be
predicted analyzing PC ability to downregulate or upreg-
ulate surface antigen expression during therapy. In addi-
tion, BM PPCs have been demonstrated to be more
immunophenotypically heterogeneous than previously
understood, and subpopulations of non-neoplastic PCs
with an immunophenotype similar to myeloma PCs have
been described (40–45). In this article, our primary end-
point was structured as follows: (1) analysis of the
expression of CD45, CD19, CD27, CD56, CD117, CD20,
CD200, CD49d, CD58, CD11a, and CD30 in MGUS sub-
jects, MM responding and relapsing patients, to test the
utility of these markers in detecting CPCs in various clin-
ical scenarios; (2) study of the differences in the immu-
nophenotype of PPCs comparing normal subjects with
responding and relapsing patients; (3) detection of varia-
tions in expression of the cited antigens on CPCs in
groups of new or treated patients, and comparison with
PPCs of MRD negative and normal subjects. As second-
ary endpoint we determined the existence of a correla-
tion between exordium of disease/response to therapy/
disease progression and the expression of the listed
markers on PPCs and CPCs; then we verified if such a
correlation is influenced by most commonly considered
clinical and prognostic variables. The inclusive objective
is to define the utility of PPCs analysis in MM diagnosis
and follow up, and the possibility of elaborating disease
stage related MFC panels. In our knowledge, this is the
first time that this kind of approach has been used to
evaluate the expression of all these markers simultane-
ously in the same group of subjects.
MATERIALS AND METHODS
Patients and BM Samples
A total of 60 subjects (42 male and 18 female) were
included in this study. Control specimens consisted of
10 BM samples from patients who were suspected to
have a haematological disease and revealed to be non
oncological subjects (Control group). These patients
have no history of MM, MGUS or lymphoid/myeloid neo-
plasm. BM samples of 40 patients with MM and 10
patients with already documented (7 subjects) or newly
diagnosed (3 subjects) MGUS submitted to our labora-
tory for routine analysis were evaluated by MFC and
morphology. For every patient clinical chemical and
immunological profiles, as well as reference intervals
were provided by the U.O. Patologia Clinica – Labora-
torio Analisi Cliniche of ARNAS Civico, Palermo (Italy).
Clinical data and history for MGUS and MM cases were
provided by U.O. Oncoematologia of ARNAS Civico,
Palermo (Italy). Disease stage was defined according to
Durie-Salmon and ISS staging criteria (46,47). Response
to therapy was defined according to Bird et al. (48). Of
MM samples, 10 were obtained at presentation (group
New), 10 from patients with progressive disease (group
Progressive), 10 from patients in partial remission (3
very good partial response, 6 partial response and 1 sta-
ble disease – group Therapy) and 10 from patients that
achieved stringent CR (group Complete). All MGUS
patients were considered as a separate group (MGUS
group). Informed consent procedures and forms were
proposed to and approved by the ARNAS Civico Medical
Ethics Committee. Written informed consent was given
by all subjects in line with the Declaration of Helsinki
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Protocol. BM samples were collected in EDTA tubes and
processed in one hour since collection.
Multiparameter Flow Cytometry
Details about antibodies and instrument are indicated
in on line Supporting Information Tables SI1 and SI2.
Specimens were fragmented with a sterile syringe and
filtered using a 80lm filter; nucleated cells were enum-
erated using UniCelVR DxHTM 800 CoulterVR Cellular Anal-
ysis System (Beckman Coulter, Miami, FL) and brought
to a final concentration of 106cells/100ll with PBS w/o
calcium and magnesium (EuroClone, Milan, Italy). Com-
binations of antibodies used to stain surface and intracel-
lular markers are listed in Table 1. For staining of surface
markers, 100ll of each sample were incubated with the
opportune combinations of antibodies for 15 minutes in
the dark. Erythrocytes were lysed adding 1 mL of Versa-
LyseTM Lysing Solution and incubating tubes for 20
minutes in the dark. For intracellular staining of kappa
and lambda light chains, 50ll of sample were washed 5
times with 2 mL of PBS w/o calcium and magnesium
(EuroClone, Milan, Italy), and processed with PerFix-nc
(Beckman Coulter, Miami, FL) following instructions.
Samples were all acquired with NaviosTM Flow Cytome-
try System, data were collected with Navios v1.0 Soft-
ware (Beckman Coulter, Miami, FL) and then analyzed
with KaluzaVR Flow Cytometry Analysis Software v1.2
(Beckman Coulter, Miami, FL). Daily testing of instru-
ment was performed as indicated: standardization of
light scatter, fluorescence intensity and optimal hydrody-
namic focusing instrument settings were verified using
Flow-Set Pro Fluorospheres (Beckman Coulter, Miami,
FL); compensation matrix for each combination of anti-
bodies was tested with CYTO-COMPTM Cell Kit (Beck-
man Coulter, Miami, FL); optical alignment and fluidics
were checked using Flow-Check Pro Fluorospheres
(Beckman Coulter, Miami, FL). To identify PCs, a combi-
nation of CD38, CD138, and CD45 together with side
scatter properties was used; the first gate was set on
CD38 versus CD138 as suggested (10). Distinction
between normal/reactive and clonal PC compartments
was performed on the basis of their most frequent aber-
rant phenotypes (as regards CD38, CD19, CD27, CD56,
and CD45); results were confirmed by the presence of
clonal restriction in population showing the abnormal
phenotype, and the absence of restriction in normal PCs
(10,22). The j:k ratio was defined as abnormal if< 0.5
or> 3 (49). A minimum of 200 events were collected in
the PC gate for each tube; to reach this result, a total of
200,000–2,000,000 events were acquired. For each
marker, an internal negative population present within
the sample was used to define gates and sample fluores-
cence background (23,50). Data were measured as per-
centage of cells presenting the antigen (percentage of
positive cells) and Mean Fluorescence Intensity Ratio
(MFI ratio). MFI ratio for each fluorochrome-marker con-
jugate was defined as the geometric mean fluorescence
of the positive population normalized for the geometric
mean fluorescence of the negative population. Cellular
DNA content and ploidy were analyzed by
CYCLOSCOPE-MM (Cytognos, Salamanca, Spain) follow-
ing instructions. DNA index was used to define the pres-
ence of aneuploidies as follows: hypodiploidy when the
DNA index was <0.95, pseudodiploidy when the DNA
index was 0.95–1.05 (excluding those subjects with
DNA index of 1, who were indicated as perfect diploid),
hyperdiploidy (HRD) when DNA index was >1.05, and
near tetraploidy when DNA index was >1.75 (51).
BM Film Staining
BM films were prepared and stained with May-
Gr€unwald-Giemsa staining method as described else-
where (52,53). All reagents were supplied by Merck
Millipore, Darmstadt, Germany.
Statistical Analysis
Continuous non normal data are expressed as median
values (range); normal variables are indicated as
mean6SD. Baseline differences between groups were
assessed by the v2 test or Fisher’s exact test, as needed
for categorical variables. The univariate analysis of var-
iance (ANOVA) was performed for parametric variables,
and post hoc analysis with the Tukey’s test was used to
determine pairwise differences. The Kruskal-Wallis statis-
tic test was performed for nonparametric analysis. The
Wilcoxon signed-rank test was used to evaluate intra-
group difference. For multiple comparisons the Bonfer-
roni correction was performed. Multinomial logistic
Table 1
Combinations of Antibodies
FITC PE PC5.5 PC7 APC
APC-Alexa
Fluor 750 PB KO
Tube 1 Cyt j Cyt k CD38 CD56 CD138 CD27 CD19 CD45
Tube 2 CD20 CD56 CD38 CD117 CD138 CD27 CD19 CD45
Tube 3 CD11a CD200a CD38 CD56 CD138 CD27 CD19 CD45
Tube 4 CD30a CD58 CD38 CD56 CD138 CD27 CD19 CD45
Tube 5 CD49da CD38 CD56 CD138 CD27 CD19 CD45
Cyt: cytoplasmic; FITC: fluorescein isothiocyanate; PE: phycoerythrin; PC5.5: phycoerythrin-cyanin 5.5; PC7: phycoerythrin-
cyanin 7; APC: allophycocyanin; PB: pacific blue; KO: krome orange.
aAll antibodies were purchased from Beckman Coulter (Miami, FL), except those with which were purchased from BD Pharmin-
genTM (San Jose, CA).
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regression analysis examined the correlation between
various patients groups (dependent variables) and
markers measurements (independent variable) in simple
and multiple regression models. v2 and Likelihood Ratio
v2 statistics were used in assessing goodness of fit in
Regression model. Data were analyzed by the Epi Info
software (version 6.0, Centers for Disease Control and
Prevention, Atlanta, GA) and IBM SPSS Software 21.0
version (IBM Corp., Armonk, NY). All P-values were
two-sided and P< 0.05 was considered statistically
significant.
RESULTS
Characteristics of Patients
Characteristics of patients and statistical significant dif-
ferences as regards sex, stage, and therapies are summar-
ized in Table 2. Examining age, MGUS patients (70.96 5.6
years) were significantly older than Control and Complete
subjects (58.36 5.8 and 59.86 8.5 years, respectively; vs.
Control P5 0.008 and vs. Complete P5 0.027). Progres-
sive patients (80.36 4.2 years) also presented a more
advanced age compared with Control, Complete, and
Therapy (61.96 9.5 years) (P< 0.0005 in all cases), and
with New subjects (66.36 10.8 years, P5 0.002). When
MFC analysis was performed, 40% of Complete, 30% of
Therapy and 30% of Progressive patients have interrupted
treatment from at least 15 days. Lenalidomide was the
treatment of choice in 40% of Complete and 20% of Pro-
gressive cases. Thalidomide as monotherapy was adminis-
tered to 20% of Complete subjects. Bortezomib-
dexamethasone therapy was taken by 20% of Therapy
and 50% of Progressive patients (Progressive vs. Complete
P5 0.032). In Therapy group, 20 and 30% of subjects
underwent bortezomib-cyclophosphamide-dexamethasone
and bortezomib-thalidomide-dexamethasone regimens,
respectively. Statistical analysis was extended to therapeu-
tic regimens administered to patients before the time of
this study. Frequencies of each type of therapeutic regi-
men was recordered. Significant differences were found
for vincristine-melphalan-cyclophosphamide-prednisone
(VMCP) therapy, only given in 50% of progressive cases
(Progressive vs. Complete and Therapy P5 0.032), and
bortezomib-thalidomide-dexamethasone (VTD) regimen,
used in 20% and 50% of Complete and Therapy patients,
respectively, (Therapy vs. Progressive P5 0.032). Clinical
variables recorded for each group are indicated in Table
3. Patients in each group were also subgrouped depend-
ing on presence of serum albumin 3.5 or <3.5 g/dL,
serum creatinine levels< or 2 mg/dL and M protein pro-
duction rates low, high or comprised between 5 and 7 g/
dL (for IgG) and 3 and 5 g/dL (for IgA), just as reported
for Durie-Salmon and ISS staging criteria, but in these
cases no significant difference emerged (data not shown).
In addition, data about presence of eventual comorbidities
were recorded. No significant differences were observed
Table 2
General Characteristics of Subjects Included in This Study
Control MGUS Complete Therapy New Progressive PW comp
Sex M 100% (10) 70% (7) 40% (4) 80% (8) 30% (3) 100% (10) Ct, P vs. N 0.02
F 30% (3) 60% (6) 20% (2) 70% (7)
Time fd 768.1 (7) 361.8 1.561.5 060 4.461.8 M vs. T 0.021
(years) M vs. N 0.002
Subtype IgA k 30% (3) 30% (3) NT
IgA j 10% (1) 50% (5) NT
IgG k 30% (3) 20% (2) 30% (3) 60% (6) NT
IgG j 50% (5) 40% (4) 40% (4) 10% (1) 50% (5) NT
k 40% (4) 20% (2) NT
j 20% (2) NT
D-S Stage I A 20% (2) 30% (3) 70% (7) T vs. P 0.003
II A 20% (2) 50% (5) 50% (5) 30% (3)
II B 10% (1) 10% (1)
III A 60% (6) 10% (1) Cp vs. N, P 0.01
III B 30% (3) 10% (1)
ISS Stage I 10% (1) 30% (3) 40% (4)
II 90% (9) 40% (4) 30% (3) 80% (8) Cp vs. N 0.02
III 30% (3) 30% (3) 20% (2)
ASCT 60% (6) 50% (5) Cp vs. P 0.01
T vs. P 0.032
Continous variables are indicated as mean6SD; other results are expressed as percentage of cases. The number of subjects is
indicated between brackets. Y, years; Time fd, time passed from diagnosis of the disease; k, myeloma secerning only lambda chain;
j, myeloma secerning only kappa chain; D-S stage, Durie-Salmon stage; ASCT, autologous stem cell transplantation; PW comp,
pairwise comparison; Ct, Control; M, MGUS; Cp, Complete; T, Therapy; N, New; P, Progressive; NT, not tested. Everytime different
pairwise comparison against one group gave the same P value, groups that were compared with that group are reported separated
by a comma.
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for chronic renal insufficiency, hypothyroidism, obesity,
thalassemia trait, HCV, and HBV related chronic hepatitis
(data not shown). Diabetes interested 20% of Complete,
40% of MGUS and 70% of Progressive subjects (Progres-
sive vs. Control, Therapy and New P5 0.003 in all cases).
Cardiopathy was a complication in 20% of MGUS and
50% of Progressive patients (Progressive vs. all other
groups except MGUS P5 0.032). Hypertension was
observed in 40% of complete and new, 50% of therapy
and 80% of progressive subjects (progressive vs. control
and MGUS P5 0.007; therapy vs. control and MGUS
P5 0.032).
PCs Analysis and Intragroup Comparisons between
PPCs and CPC
As evidenced by morphology, at the time of diagnosis
mean percentage6 SD of PC was 6.46 2.4% for MGUS,
296 7.4% for Complete, 33.56 14.7% for Therapy, and
296 11.7% for Progressive (MGUS vs. complete and pro-
gressive P5 0.001; MGUS vs. Therapy P< 0.0005).
Instead, at the time of this study, values changed as fol-
lows: 16 0% for Control, 66 2.1% for MGUS, 2.16 1.6%
for Complete, 10.46 10.5% for Therapy, 206 7.8% for
New, and 296 22.2% for Progressive (Progressive
vs.Control, MGUS and Complete, and New vs. Control
P< 0.0005 in all cases; MGUS vs. New P5 0.049; Com-
plete vs. New P5 0.005; Therapy vs. Progressive
P5 0.003). Median percentages of PCs (range) detected
by MFC were 1.9% (1.4–2%) for Control, 1.5% (0.4–
2.4%) for MGUS, 0.5% (0.05–0.7%) for Complete, 0.9%
(0.2–13.5%) for Therapy, 8.7% (1.6–18.8%) for New and
3.8% (1.4–35.2%) for Progressive (Complete vs. Control
P5 0.015; Complete vs. New and Progressive
P< 0.0005 in both cases; Therapy vs. New P5 0.036).
Median values (range) of CPCs of total PCs were 79.5%
(64–87.2%) for MGUS, 64.8% (2.8–99.8%) for Therapy,
98.2% (89.5–99.6%) for New and 98.9% (91.3–99.1%) for
Progressive (MGUS vs. New P5 0.008, vs. Progressive
P5 0.023). In Complete and Control 100% of PCs were
polyclonal, while observed median percentage values
Table 3
Clinical Characteristics of Patients
Control Mgus Complete Therapy New Progressive PW comp
CRP>0.3 20% (2) 40% (4) 40% (4) 100% (10) P vs.Ct, M <0.0005
P vs.Cp 0.0007
B2M<3.5 100% (10) 80% (8) 100% (10) 40% (4) 40% (4) P vs.Ct, Cp <0.0005
P vs.M 0.0007
B2M5.5 20% (2) 40% (4) 30% (3) 50% (5) P vs.Ct, Cp 0.032
3.5B2M<5.5 20% (2) 30% (3) 50% (5) P vs.Ct, M, Cp 0.032
HB<8.5 10% (1)
HB>10 100% (10) 100% (10) 100% (10) 70% (7) 80% (8) 50% (5) P vs.Ct, M, Cp 0.032
8.5HB10 30% (3) 10% (1) 50% (5) P vs.Ct, M, Cp 0.032
BUN>25 10% (1) 20% (2) 50% (5) P vs.Ct, M, Cp 0.032
LDH>530 20% (2) 20% (2) 50% (5) P vs.Ct, M, Cp 0.032
S IFE1 100% (10) 100% (10) 100% (10) 100% (10) Ct, Cp vs.all <0.0005
U IFE1 50% (5) 80% (8) 30% (3) 80% (8) N vs.Ct, Cp;
P vs.Ct, Cp
0.0007
S AB FLC ratio
(range 0.31–1.56)
100% (10) 50% (5) 100% (10) 100% (10) M vs.Ct, Cp;
N vs.Ct, Cp;
P vs.Ct, Cp
<0.0005
U AB FLC ratio
(range 2.04–10.37)
80% (8) 10% (1) 40% (4) 50% (5) M vs.Ct, Cp 0.0007
M vs.T 0.005
Results are expressed as percentage of cases, the number of subjects is indicated between brackets. CRP>0.3, C-reactive
protein>0.3 mg/dL; B2M<3.5, b-2-microglobulin<3.5 mg/L; B2M>5.5, b-2-microglobulin>5.5 mg/L; 3.5B2M<5.5,
3.5 mg/Lb-2-microglobulin<5.5 mg/L; HB<8.5, hemoglobin<8.5 g/dL; HB>10, hemoglobin>10 g/dL; 8.5<HB<10,
8.5 g/dL<hemoglobin<10 g/dL; BUN>25, blood urea nitrogen>25 mg/dL; LDH>530, lactate dehydrogenase>530 IU/L; S IFE
1, serum immunofixation positive; U IFE1, urine immunofixation positive, S AB FLC ratio, serum abnormal free light chain ratio;
U AB FLC ratio, urine abnormal free light chain ratio; PW comp, pairwise comparisons; Ct, Control; M, MGUS; Cp, Complete; T,
Therapy; N, New; P, Progressive; all, M, T, N, P. Everytime different pairwise comparison against one group gave the same P value,
groups that were compared with that group are reported separated by a comma. Different pairwise comparisons giving the same P
value are reported separated by a semicolon.
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(range) for PPCs in the other groups were: 20.5% (12.8–
36%) for MGUS, 35.2% (0.2–97.2%) for Therapy, 1.8%
(0.4–10.5%) for New and 1.1% (0.9–8.7%) for Progres-
sive (Control and Complete vs. New and Progressive
P< 0.0005 in all cases; vs. Therapy P5 0.018). In Con-
trol and Complete group, 100% of PCs were perfect dip-
loid (Control and Complete vs. all groups P< 0.0005).
Pseudodiploidy was detected in 20% of MGUS, 10% of
Therapy and 10% of New subjects; instead, hypodiploidy
interested 20% of New patients. HRD was identified in
80% of MGUS, 90% of Therapy, 70% of New, and 100%
of Progressive subjects (Therapy and Progressive vs.
Control and Complete P< 0.0005 in all cases; Control
and Complete vs. MGUS P5 0.0007 and vs. New
P5 0.003). Ranges of expression and median values for
each studied marker on CPCs and PPCs as revealed by
MFC are indicated in Table 4. Levels of expression for all
studied markers expressed as MFI ratio are reported in
Table 5. The analyzed markers showed different utility
in distinguishing CPCs from PPCs in MGUS, new, ther-
apy and progressive groups, except for CD30 and
CD11a, which never showed differences comparing nor-
mal and neoplastic populations. Results for intragroup
comparisons between CPCs and PPCs in all groups are
indicated in Table 4 (ranges of positive PCs), and in
Table 5 (MFI ratio).
Definition of Normal Immunophenotype
In order to verify if PPCs are immunophenotipically
different from one group to another, we compared the
expression of all markers on PPCs from all groups.
Results are summarized in Figures 1A–1T. PPCs showed
a relevant grade of immunophenotypic heterogeneity
among groups.
Differences among Control and Complete PCs and CPCs
To define how CPCs differ from normal/reactive poly-
clonal PCs found in subjects who do not present signs
of clonal expansion, we compared the expression of all
markers on PCs in Complete and Control groups with
CPCs in MGUS, therapy, new and progressive groups.
Results are summarized in Figures 2A–2V.
Regression Analysis
Multinomial logistic regression analysis was used to
evaluate the relation existing between the expression of
MFC markers (independent variables—considered as
both percentage of positive cells and intensity of expres-
sion measured by MFI ratio) and disease status defined
as the appartenence of each patient to one precise
group (dependent variables). Significant results are sum-
marized in Table 6. As reference categories, we chose
Control in analyzing PPCs, and MGUS in studying CPCs,
since MGUS is considered a “preneoplastic” condition.
To test the hypothesis that the significant markers
remained informative also considering common prognos-
tic variables we performed a multivariate regression
analysis; among parameters showing statistical signifi-
cant differences in this study, we selected age, sex,
Durie-Salmon, and ISS stages at diagnosis, ASCT and
HRD, since they were considered highly reliable in
determining prognosis, and allowed us to obtain
the best fitting models. Other variables did not exhibit
explicative power in our model (data not shown).
Results are indicated in Table 6.
DISCUSSION
Since the 90’s, multiparameter immunophenotyping
has been providing relevant information for the diagno-
sis, classification and monitoring of hematological malig-
nancies. Immunophenotypic differences between nor-
mal and neoplastic cells are essential in detecting MRD
in myeloma when there are fewer than 5% of PCs by
morphologic examination and a very small percentage
of PCs to detect clonality by histological examination.
Moreover MFC immunophenotyping may be useful to
define potential prognostic markers and new therapeu-
tic targets. MFC is perceived as highly dependent on
expertise and is regarded to have limited reproducibility
in multicenter studies, mostly because of the lack of
standardization in data interpretation, analysis, and pre-
sentation, and limited evaluation of “new” vs. “classical”
markers (54). Since larger complexity of the multivariate
data analyses of both major and minor cell populations
produced new insights in what is commonly known as
“normal” phenotype (41,42), and MM and MGUS pres-
ent both a strong component of interaction between
neoplastic compartment and surrounding cells, includ-
ing residual PPCs, there is the urgent need to review
phenotypic differences among subjects. In this study,
we propose an accurate approach to investigate the role
of various immunophenotypic markers in discriminating
CPCs from PPCs. We clearly demonstrate that PPCs are
not equal among patients, showing a great variability in
terms of percentage of positive cells and levels of
expression of many antigens. Immunophenotypic differ-
ences in CPCs between MGUS and MM subjects, as well
as changes in the immunophenotype of MM CPCs after
therapy have been described (14,18,24,45); here we
observe that these changes may also interest PPCs. We
focused our attention on some markers involved in cel-
lular adhesion (CD49d, CD11a, and CD58), because a
better understanding of quantitative changes in expres-
sion of adhesion molecules during the stages of the dis-
ease may be fundamental for defining the mechanisms
by which the PCs adhere to or detach from the BM
niches (32). We also analyzed the expression of CD30,
which is present normally on only a very small fraction
of activated lymphocytes. CD30 contributes to negative
selection of T-cells, and could be an attractive target for
therapeutic intervention (55). The classic immunophe-
notype of myeloma PCs has been described as CD38
bright positive (dimmer than normal PCs), CD138 posi-
tive, CD19 negative, CD45 dim to negative and CD56
positive with CD20 and CD117 positivity in selected
cases (10,22,23,40). However recent reports demon-
strate that PPCs could display a CD201CD561CD45-
CD19- phenotype (40–42,56). Precedent studies
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Table 4
Ranges of Expression for the Studied Markers in All Groups
% of positive CPCs % of positive PPCs
P valueMedian Min Max Median Min Max
CD45 Control 98.9 54.7 99
MGUS 89.2 33.8 97.8 99.1 80.3 100 0.005
Complete 92.2 76.5 99.9
Therapy 26.7 11.1 100 97.6 89.1 100 0.011
New 87.2 12.7 99.6 98 0 100
Progressive 89.9 3.7 98.2 100 78.8 100 0.005
CD19 Control 72.4 58.9 87.4
MGUS 0 100 0.002
Complete 50 33.5 86.6
Therapy 0 0 95.3 96.1 13.6 100 0.01
New 2.8 0 95.6 100 0 100
Progressive 0 100 0.002
CD56 Control 4.8 4.7 5.6
MGUS 23 4.8 92.9 27.5 24.1 35.7
Complete 12 0 18.6
Therapy 95.1 0 100 10 0 100 0.05
New 95.8 4.9 100 10 10 35.3 0.023
Progressive 96.2 86.7 98.5 25.3 10 26.4 0.005
CD49d Control 88.4 48.5 100
MGUS 48.7 42.9 88.6 75 74.2 91.9 0.012
Complete 90.8 78.4 100
Therapy 77.9 34.6 100 86.5 59.9 100 0.028
New 74.2 25.3 92.8 73.9 50 100
Progressive 74.6 50.8 100 100 45.7 100
CD30 Control 2 0 3
MGUS 1.1 0 3.8 0 0 5.4
Complete 0 0 24.5
Therapy 0.6 0 68 0 0 12.5
New 3.1 0 9.8 3.4 0 37.3
Progressive 1 0 43.6 0 0 100
CD58 Control 96.1 92.2 100
MGUS 95.9 94.7 96.4 96.9 92.6 99.2
Complete 98.8 83.9 100
Therapy 98.4 57.7 100 90.2 82.7 100
New 94.1 58.2 100 100 96.5 100
Progressive 94.9 59.8 98.2 100 93.5 100 0.005
CD11a Control 96.6 81.5 98.9
MGUS 98.3 97.1 99.3 98.2 89.2 98.8
Complete 83.7 64.7 100
Therapy 96.4 79.6 100 94.9 93.2 100
New 98.6 88.1 100 100 99.7 100
Progressive 98.4 20.4 99.3 97 64.7 98.4
CD117 Control 0
MGUS 85.4 15.2 94.7 0 0.005
Complete 0
Therapy 62.6 0 100 0 0.012
New 21.4 0.3 71.7 0 0.027
Progressive 49.7 26.2 64.9 0 0.005
CD27 Control 98 97.3 100
MGUS 77.7 31.8 100 93.8 83.4 100 0.017
Complete 97.3 94.2 100
Therapy 97.8 0 100 98.2 45.5 100
New 80.9 11.6 100 100 28.3 100
Progressive 55.4 19.5 100 85.3 72.4 96.5 0.012
CD200 Control 1.3 0 7
MGUS 10.6 6.4 42.7 29.7 17.8 65.9 0.035
Complete 15.5 5.1 100
Therapy 53.2 0 88.6 36.3 0 69
New 90.4 0.6 99.2 57.5 28.7 69.2
Progressive 54.1 17.8 83.4 48.7 11.9 60.7
CD20 Control 0
MGUS 2.4 0 9.2 3.3 0 9.1
Complete 4.3 0 26.1
Therapy 8.5 0 72.7 9.6 1.9 64.6
New 0 0 99.6 0 0 2.7
Progressive 0.8 0 4.1 6.6 0 28 0.038
P values referred to intragroup pairwise comparison between CPCs and PPCs are indicated.
Min: minimum; Max: maximum.
Table 5
Levels of Expression of the Studied Markers in all Groups
MFI Ratio for CPCs MFI ratio for PPCs
Median Min Max Median Min Max P value
CD45 Control 12.1 4.7 16.3
MGUS 5 4.4 10.5 12 8.4 16.4 0.005
Complete 11.1 4.3 24.7
Therapy 5.2 2.8 25.3 8.1 3.8 23.3
New 9.4 3.5 23.5 5.5 1 20.4
Progressive 7.6 4.3 9.3 22.3 11 25 0.005
CD19 Control 11 6.2 15.7
MGUS 1 9.2 8.6 26.1 0.005
Complete 8.7 6.7 16.4
Therapy 1 1 20.1 8.2 5.2 17.1
New 5.3 1 11.6 7.8 1 7.9
Progressive 1 9 6.5 16.1 0.005
CD56 Control 16.5 9.4 17.7
MGUS 13.1 11 19.3 16.8 8.4 47.2
Complete 10.1 1 63.4
Therapy 13.9 1 43.4 10.2 1 31.4
New 13.3 6.1 19.9 16.7 13 27.3 0.027
Progressive 15.8 5.9 18 14.4 11.4 19
CD49d Control 17.4 11.4 18.2
MGUS 14.5 10.1 25.1 19.9 19.1 20.6
Complete 21.1 8.5 43.6
Therapy 11.8 6.1 39.4 15.3 7 43.4
New 11.2 5.5 24.6 13.5 11.1 16.7 0.027
Progressive 8.2 5 12.5 12.8 6.1 35.1 0.035
CD30 Control 6.5 1 8.2
MGUS 9.8 1 10.7 1 1 11.2
Complete 1 1 20.7
Therapy 4.1 1 39.3 1 1 8.6
New 7.3 1 10.9 6 1 12.4
Progressive 4.5 1 8.3 1 1 11.9
CD58 Control 10.2 4 19.5
MGUS 7.6 7.2 16.7 11.8 8.5 14.8
Complete 12.5 6.6 21.1
Therapy 8.9 3.2 30.2 5 3.7 10.5
New 6.8 3.7 34.6 11.7 5.3 29.1
Progressive 10.3 4 12.2 21.8 7.2 35.1 0.005
CD11a Control 3.8 3.2 4.6
MGUS 4.7 4.3 5.5 4.6 3.7 5.8
Complete 4.5 3.3 5.7
Therapy 4.6 3.7 18.1 5 3.1 7.6
New 6.4 3 15.8 8.1 5.1 17.2
Progressive 5.7 2.1 9.2 5.8 4.1 16.5
CD117 Control 1
MGUS 14.4 8.6 14.7 1 0.005
Complete 1
Therapy 7.3 1 23 1 0.012
New 10.7 6.9 16.3 1 0.027
Progressive 6 5 11.6 1 0.005
CD27 Control 38.7 19.9 47.3
MGUS 37.1 7.9 55.8 46.8 24.5 67.8 0.027
Complete 42.2 12 55
Therapy 29.2 1 62.5 51.6 6 104.2
New 11.6 3.6 30.7 21.1 14.5 34.3
Progressive 15.7 6.4 44.1 35.8 21 58.4 0.005
CD200 Control 5.2 1 5.8
MGUS 7.4 6.3 8.2 8.2 7.7 8.3 0.005
Complete 8 1.3 12.6
Therapy 6.8 1 16.8 8.5 1 12.9
New 15.2 7.2 43.4 9.5 9 10
Progressive 7.8 4.8 11.6 8.6 5.9 15.4 0.005
CD20 Control 1
MGUS 16.9 1 44.2 18.8 1 37.6
Complete 6.3 1 36.5
Therapy 12.2 1 42.1 14.4 4.4 46.1
New 1 1 30.6 1 1 16.9
Progressive 16.9 1 32 3.3 1 37.7
P values referred to intragroup pairwise comparison between CPCs and PPCs are indicated. Min, minimum; Max, maximum.
FIG. 1. A–J: Immunophenotypic differences in PPCs among groups.
Box plots indicate the median and 25th and 75th percentiles. Whiskers
indicate minimum and maximum values. •,*5 outliers. The following
markers exhibited statistically significant differences as regards the
mean percentage of positive cells: CD19 (P<0.0005), CD56
(P<0.0005), CD58 (P50.004), CD11a (P50.01), CD27 (P50.01),
CD200 (P<0.0005), and CD20 (P<0.0005). Also statistically signifi-
cant differences as regard MFI ratios were demonstrated: CD45
(P50.005), CD49d (P50.02), CD58 (P50.011), CD11a
(P<0.0005), CD200 (P50.001), and CD20 (P50.008). P values of
pairwise comparisons are indicated. CD117 is never expressed on PPCs
(data not shown). Levels of expression of CD45 were higher in Progres-
sive than in New and Therapy (A,B). The proportion of CD191 PCs was
lower in Control and Complete than in MGUS and Progressive (C,D).
Median percentage of CD561 PCs was lower in Control versus MGUS
and Progressive, and in Complete versus MGUS (E,F). Levels of expres-
sion of CD49d did not exhibit statistically significant differences at post
hoc analysis (G,H). CD30 did not show variability in expression among
groups (I,J). K–T: Immunophenotypic differences in PPCs among groups.
Box plots indicate the median and 25th and 75th percentiles. Whiskers
indicate minimum and maximum values. •,*5 outliers. P values of pair-
wise comparisons are indicated. CD581 fraction was littler in Therapy
than in New and Progressive; also levels of expression of CD58 were
lower in Therapy than in Progressive (K,L). CD11a1 fraction was larger
in New than in Complete and Progressive; moreover expression of
CD11a was less intense in Control than in Progressive and New (M,N).
the proportion of CD271 PCs was lower in Progressive versus Control
and New (O,P). CD200 was expressed by a less extended percentage of
PCs in Control than in MGUS, New, Progressive and Therapy. MFI ratio
for CD200 was lower in Control than in New, Therapy and Progressive
(Q,R). Median percentage of CD201 PCs was higher in Therapy than in
Control and New. Intensity of expression of CD20 was reduced in PCs of
Control compared with MGUS and Therapy (S,T). [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.com.]
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FIG. 1. Continued. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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explored immunophenotype of PPCs only in healthy
individuals (42,56), while others reunited in the same
category PPCs of healthy and pathological subjects
(40,45), causing a loss of information related to possible
PPC heterogeneity among different categories of
patients. Analyzing our data, it can be easily noted that
for CD19, CD45, CD27, and CD117 percentages of posi-
tive PPCs reflect the ranges found in precedent studies
(10,22,23,40–42,56,57); CD20 was never expressed on
PCs in Control group, but the range of expression was
broad on PPCs in all other groups. CD200 was
expressed on both normal and neoplastic PCs, as previ-
ously reported (10,58). CD58, CD49d, and CD11a were
never completely absent on PPCs and CPCs, while fre-
quency of CD301 cells was modest in both plasmacellu-
lar compartments in all groups (36). In this study, range
of expression for CD56 (NCAM – Neural Cell Adhesion
Molecule) on PPCs essentially did not depart from those
described elsewhere (40,42,56), except for an outlier
identified in Therapy; however expression close or cor-
responding to 100% for this antigen has occasionally
been reported (32,56). The proportion of CD561 PCs is
constantly described to be low in BM of healthy controls
(10,57), however CD561 PCs may be artificially low in
MFC analysis; acting as an anchor, CD56 could make
PCs more resistant to BM aspiration (42). Focusing on
ranges of expression on PPCs, we observed that CD561
fraction is reduced in Control than in MGUS and Pro-
gressive, and in Complete than in MGUS. This is openly
conflicting with report by Perez-Andres et al. who
described no phenotypic differences for CD56 between
PCs from healthy individuals and PPCs from MGUS sub-
jects (45). This discrepancy may be explained consider-
ing differences in gating strategies, and in the use of
monoclonal antibody clones or fluorochromes between
the cited study and ours. As expected, CD561 CPCs
were more numerous than CD561 PPCs in New, Pro-
gressive, and Therapy; the same type of relation was
maintained in comparisons with Control and Complete
PCs. However, in New, MFIs ratio of PPCs was higher
than that of CPCs; to the best of our knowledge, this
observation has never been described since the intro-
duction of >4 color FC in analysis of MM patients. On
the basis of these results, the expression of CD56 on
PPCs should be further elucidated. CD45 on PPCs is
reported to be expressed heterogeneously
(10,22,23,40,57); in our study it was effective in distin-
guishing PPCs from CPCs in MGUS, Progressive and
Therapy. Expression of CD45 was more intense on PPCs
in Progressive than on PPCs in New and Therapy. Con-
sidering that CD45 expression characterizes proliferating
compartment of normal, reactive and malignant PCs
(13,22), this increased level of expression on Progressive
PPCs may depend on the proliferative BM microenviron-
ment to which all PCs of relapsing subjects are exposed
(24). CD19 is downregulated in PCs maturation, and
CD19-CD561 PCs are believed to represent long lived
terminal stage PPCs (22,40). CD19 was persistently neg-
ative in MGUS and Progressive CPCs. This pattern of
expression has already been described in literature
(22,40), although cases of CD191 MGUS cells have
been reported (22). Clearly, PCs from Control and Com-
plete exhibited a reduced CD191 fraction compared to
PPCs from MGUS and Progressive. Exact mechanism rul-
ing expression in MGUS and Progressive subjects
remains to be explored. CD27 is strongly expressed on
PPCs (9,10,56), but CPCs are reported to be weak or
negative (9,10,57); in our study it showed no differences
in expression comparing CPCs with Control and Com-
plete PCs, contradicting previous data (9), probably
because of discrepancies in methods or the small sample
size. We evidenced that CD271 Progressive PPCs were
less numerous than CD271 PPCs of New and Control.
Since this antigen is involved in apoptosis induced by
CD27–CD70 interactions (59), it would be interesting to
evaluate if other molecules required for programmed
cell death show variable expression in PPCs of Progres-
sive patients. CD117 was never present on normal PCs,
thus being highly effective in distinguishing PPCs from
CPCs (when present on CPCs). The data about CD20 in
PCs of healthy people are conflicting. Reported ranges
vary from a minimum of 0 to maximum of 91%
(10,22,40,56,57), but it is universally accepted that low
CD20 expression is associated to PC maturity. Expres-
sion of CD20 on MM cells is reported to range from 2
to 90% (42). CD20 was a poor antigen in distinguishing
CPCs from PPCs, as previously described (56), except in
Progressive group, in which proportion of CD201 PPCs
was higher than proportion of CD201 CPCs. Expression
of CD20 on CPCs is associated t(11;14) (Refs. 22) and
(23)); since cytogenetic analysis was not performed, we
can not say if t(11;14) is present in Progressive CPCs. In
FIG. 1. Continued. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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FIG. 2. A–L: Results of comparisons among PCs of Control and
Complete and CPCs of MGUS and MM groups. Box plots indicate the
median and 25th and 75th percentiles. Whiskers indicate minimum
and maximum values. •,*5 outliers. Kruskal-wallis test revealed that
the following markers showed statistically significant differences as
regards the median percentage of positive cells among groups: CD19
(P<0.0005), CD56 (P<0.0005), CD117 (P<0.0005), CD200
(P<0.0005), and CD20 (P50.004). Moreover, statistically significant
differences in intensity of expression emerged among groups for: CD19
(P<0.0005), CD49d (P<0.0005), CD11a (P50.01), CD117
(P<0.0005), CD200 (P<0.0005), and CD20 (P50.013). P values of
pairwise comparisons are indicated. CD45 did not show variability in
expression among groups (A,B). Median percentage of CD191 PCs in
Control was higher than in MGUS and Progressive; also CD191 fraction
of PCs was larger in Complete than in Progressive and MGUS. Levels of
expression of CD19 were higher in Control and Complete than in MGUS
and Progressive (C,D). Proportion of CD561 PCs was lower in Complete
than in Progressive, and in Control than in New, Therapy, and Progres-
sive (E,F). Levels of expression of CD49d were higher in Complete and
Control than in Progressive (G,H). CD30 did not show variability in
expression among groups (I,J). CD58 did not exhibit any statistical sig-
nificant difference (K,L). M–V: Results of comparisons among PCs of
Control and Complete and CPCs of MGUS and MM groups. Box plots
indicate the median and 25th and 75th percentiles. Whiskers indicate
minimum and maximum values. •,*5 outliers. P values of pairwise
comparisons are indicated. Intensity of expression of CD11a was lower
in Control versus Progressive and New (M,N). Since PPCs did not
express CD117, the difference of Control and Complete versus all other
groups was extremely significant, except versus New (P50.16). MFI
ratio measured for CD1171 cells was different comparing Control and
Complete versus New, MGUS and Therapy (O,P). CD27 was homogene-
ous in its expression comparing all subjects (Q,R). CD2001 fraction is
less extended in Control than in CPCs of New, Therapy and Progressive.
Levels of expression of CD200 were higher in New versus Control (S,T).
CD201 proportion of PCs was lower in Control than in Therapy. Inten-
sity of expression of CD20 was reduced in Control versus MGUS (U,V).
[Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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addition, deeper molecular studies are necessary to
explain the reasons why MFI ratio was reduced in Con-
trol versus MGUS CPCs and PPCs. Therapy PPCs
showed upregulation of CD20 compared with Control
and New PPCs, and also proportion of CD201 CPCs in
Therapy is larger compared with Control PCs. Recently
a study described the transcriptional effects of bortezo-
mib on human myeloma cell lines, showing a
FIG. 2. Continued. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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downregulation of many antigens but no effect on CD20
expression (60). Since in this study 70% of Therapy
patients are currently treated with bortezomib contain-
ing regimens, we hypotize that instead bortezomib
could directly influence expression of CD20 in PCs,
although confirmation with larger groups of patients is
necessary to confirm or reject this hypothesis. CD200 is
a cell surface glycoprotein expressed on normal B-cells
and some T-cell subsets; the expression of CD200
showed to be positive on MM PCs up to 78% (27,61).
CD200 on PPCs has been poorly investigated, and no
clear range of expression has been defined; however
our data match with both papers reporting its absence
(26,56) and those indicating positivity (10,58). Evaluat-
ing its utility in CPC detection, we observed that in
MGUS CD200 was expressed by a higher percentage of
PPCs vs.CPCs. In addition, expression was more intense
on MGUS and Progressive PPCs vs. MGUS and Progres-
sive CPCs. Defining normal phenotype, Control PCs
showed less extended fraction of CD2001 cells vs.
MGUS, New, Progressive, and Therapy PPCs, and a
dimmer expression vs. MM groups. Comparing Control
and Complete PCs with CPCs, once again Control dis-
played a smaller proportion of CD2001 cells vs. Ther-
apy, New, and Progressive. CD2001 positive cells pres-
ent reduced immunogenicity compared with normal
lymphocytes (27) and absence of CD200 correlates with
a better prognosis compared to its presence in MM (12);
on this basis, we would have expected a higher expres-
sion of CD200 in Progressive patients vs. Complete.
Deeper investigation on relapse molecular mechanisms
is necessary before excluding a role of CD200 in pro-
gression of MM. CD11a, the integrin a subunit of LFA-1,
has been reported positive as well as negative in litera-
ture on MGUS and MM samples (28,30). The ranges of
expression on CPCs are really different from one paper
to another, ranging from 0% to 100% in newly diagnosed
or remitting subjects, and from 0 to 80% in relapsing
subjects (32), or reported as <30% for CD451 cells and
10% for CD45- cells (34). On PPCs, it has been
reported to range from 20 to 100% (32). In our study,
CD11a1 proportion of CPCs showed no differences
compared to CD11a1 Control and Complete PCs, while
levels of expression of CD11a were higher on both
CPCs and PPCs of New and Progressive vs.Control PCs;
these results diverges from a precedent report demon-
strating a downregulation of CD11a in patients in
chronic phase, but in that case results might be compro-
mised by the inclusion of newly diagnosed and remitting
subjects in the same group (32). Examining PPCs,
CD11a1 fraction was expanded in New vs.Complete
and Progressive. CD58, a CD2 receptor, was previously
indicated as present occasionally on PPCs and never
expressed on MGUS CPCs (28); in our study, it is posi-
tive in a fraction of PPCs and MGUS CPCs close to
100%. This discrepancy may be attributed to differences
regarding methods (immunofluorescence microscopy vs.
MFC) and choose of control samples. CD58 was more
expressed on PPCs than on CPCs in Progressive (consid-
ering both proportion of CD581 cells and MFI ratio).
Therapy PPCs showed downregulation of CD58 vs.New
and Progressive. These data suggest that CD58 should
be considered in further studies to assess its ability in
predicting response to therapy or progression of disease
when evaluated on non neoplastic population. We did
not notice any difference comparing Control and Com-
plete with CPCs, contrary to previous data (28).
CD49d, the integrin a subunit of VLA-4, has been found
strongly expressed by MM PCs (36), while mean per-
centage of positive normal PCs has been reported 75%
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Table 6
Results of Multinomial Logistic Regression Analysis
Univariate Multivariate
Independent variable PCs Exp (B) 95% CI P value Exp (B) 95% CI P value
MFI ratio for CD45 PPCs 1.03 0.88–1.20 0.722a
1.06 0.91–1.23 0.472b
0.93 0.79–1.11 0.438c
0.81 0.63–1.03 0.086d
1.25 1.06–1.50 0.011e 1.23 1.04–1.46 0.015
Percentage of CD191 cells CPCs 111.1 111.1–111.1 Naf
111.6 108.9–114.4 <0.0005g 144.9 139.8–150.3 <0.0005
1 1.0h
MFI ratio for CD19 CPCs 67.6 67.6–67.6 Naf
64.6 54.9–76.0 <0.0005g 61.5 49.6–76.2 <0.0005
1 1.0h
PPCs 1.04 0.87–1.22 0.670a
0.93 0.77–1.14 0.502b
0.88 0.71–1.11 0.298c
0.57 0.36–0.89 0.016d 0.53 0.26–1.08 0.082
0.95 0.78–1.15 0.606e
Percentage of CD561 cells PPCs 1.51 1.16–1.96 0.002a 1.71 1.19–2.42 0.003
1.33 1.03–1.71 0.029b 1.53 1.08–2.16 0.016
1.48 1.14–1.92 0.004c 1.66 1.17–2.36 0.005
1.43 1.10–1.87 0.008d 1.61 1.13–2.29 0.009
1.46 1.13–1.90 0.004e 1.54 1.07–2.21 0.019
MFI ratio for CD49d CPCs 0.98 0.86–1.09 0.684f
0.94 0.82–1.08 0.394g
0.68 0.51–0.92 0.012h 0.62 0.38–0.99 0.046
MFI ratio for CD58 PPCs 0.99 0.86–1.13 0.882a
1.03 0.90–1.16 0.695b
0.64 0.45–0.93 0.019c 0.55 0.37–0.84 0.025
1.06 0.93–1.22 0.373d
1.13 0.99–1.27 0.057e
MFI ratio for CD11a PPCs 4.29 1.10–16.7 0.036a 3.19 0.63–15.9 0.158
4.01 1.03–15.6 0.045b 2.41 0.50–11.6 0.273
5.51 1.38–21.9 0.016c 4.82 1.20–19.3 0.027
10.8 2.64–44.6 0.001d 13.7 1.95–95.9 0.008
10.1 2.48–41.5 0.001e 14.1 2.74–72.4 0.02
Percentage of CD1171 cells CPCs 0.99 0.95–1.02 0.448f
0.93 0.88–0.97 0.003g 0.94 0.89–0.99 0.023
0.97 0.93–1.01 0.095h
MFI ratio for CD117 CPCs 0.84 0.66–1.06 0.143f
0.95 0.77–1.17 0.625g
0.71 0.53–0.94 0.017h 0.65 0.42–1.01 0.054
Percentage of CD2001 cells CPCs 1.04 0.99–1.07 0.057f
1.05 1.01–1.09 0.008g 1.06 1.01–1.11 0.012
1.04 1.01–1.08 0.032h 1.04 0.99–1.09 0.084
PPCs 1.31 1.07–1.61 0.009a 1.36 0.95–1.95 0.089
1.3 1.07–1.60 0.010b 1.36 0.95–1.94 0.089
1.3 1.06–1.60 0.011c 1.36 0.95–1.94 0.091
1.34 1.09–1.64 0.005b 1.38 0.97–1.97 0.073
1.32 1.08–1.62 0.007e 1.63 0.95–2.80 0.075
MFI ratio for CD200 CPCs 1.01 0.78–1.30 0.957f
1.31 1.02–1.68 0.034g 1.38 1.02–1.88 0.038
1.06 0.83–1.35 0.656h
PPCs 1.56 1.12–2.16 0.008a 2.02 1.19–3.41 0.008
1.45 1.06–1.98 0.020b 1.35 0.88–2.07 0.172
1.49 1.08–2.07 0.016c 1.73 1.11–2.70 0.016
1.8 1.12–2.65 0.003d 2.59 1.25–5.35 0.01
1.86 1.30–2.65 0.001e 2.23 1.28–3.89 0.005
aControl vs. MGUS.
bControl vs. Complete.
cControl vs. Therapy.
dControl vs. New.
eControl vs. Progressive.
fMGUS vs. Therapy.
gMGUS vs. New.
hMGUS vs. Progressive.
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(29). In our study, CD49d showed a more pronounced
expression on PPCs than on CPCs in all groups (fraction
of positive cells for MGUS and Therapy, MFI ratio for
New and Progressive), thus beeing highly useful to
refine CPC population when combined with common
used marker. Intensity of expression was higher in Con-
trol and Complete PCs vs.Progressive CPCs, so it would
be intriguing to verify if this marker has a role in drug
resistance during progression of disease. As we could
not identify a univocous pattern of expression of these
three adhesion involved markers, regulatory pathways
determining their expression should be explored individ-
ually. Continuous efforts are made in MM to improve
the sensitivity of immunophenotypic detection of PCs.
On the basis our results, we suppose that in future pan-
els of markers specific for the clinical question could be
used, with the addition of appropriate MFC markers to
the backbone ones (CD38, CD138, CD19, CD45, and
CD56); the evaluation of the disease should involve
PPCs, in order to follow progressions and explore the
opportunity to obtain predictive information. CD49d
should be universally present to distinguish CPCs from
PPCs; for MGUS diagnosis and monitoring, CD20 and
CD200 are suggested to be added; newly diagnosed
patients may benefit the addition of CD11a; assessment
of disease progression or response to therapy would be
more accurate by the introduction of CD27, CD58,
CD11a, and CD20. The prognostic value of specific anti-
genic profiles (CD19, CD117, and CD27) has already
been assessed; positive staining for CD19 and absence
of CD117 detected on clonal PCs were associated with
significantly shorter progression free survival and OS
(overall survival) rates of MM patients. Moreover, OS
rates were higher in patients with CD271 MM than in
those who were CD27- (57,62,63). The absence (or
presence) of CD200 expression in MM cells is predictive
for event-free survival independently of ISS stage or b-2-
microglobulin serum levels (12). For CD45 and CD56
results from precedent studies are contradictory, and
require further investigation (24,57). No information is
available about the prognostic value of the other
markers used in this study, or about their role in predict
response to therapy and disease progression, and their
utility in distinguishing disease stages without consider-
ing other clinical variables. To see if a correlation exists
between the expression of each marker and the attribu-
tion of the patients to their own groups, we performed
a multinomial logistic regression analysis; results surpris-
ingly revealed that the most abundant associations
regarded PPCs, with percentage of cells positive for
CD200 and CD56, and levels of expression of CD45,
CD19, CD58, CD11a, and CD200 showing statistical sig-
nificance. In addition, fractions of CPCs positive for
CD19 and CD200, and intensity of expression of CD19,
CD49d, CD117, and CD200 on CPCs were significant.
But when the model was elaborated again including sig-
nificant prognostic variables (37,38,43), percentage of
CD2001 PPCs and levels of expression of CD117 on
CPCs and CD19 on PPCs loosed their association, as did
levels of expression of CD11a comparing Control with
Complete and MGUS PPCs, MFI ratio for CD200 analyz-
ing Control vs. Complete PCs, and percentage of
CD2001 CPCs comparing MGUS vs. Progressive. This is
not surprising, since other works have already demon-
strated relations between variation in expression of MFC
markers and BM features (64). Our data comfort the
hypothesis that, in assessing the predictive/prognostic
values of MFC markers and their utility in following dis-
ease steps, immunological-biochemical-hematological
profile must not be ignored since it is the “mirror” of
the altered BM microenvironment influencing/being
influenced by PC phenotype (37,64). However CD19
and CD49d on CPCs, and CD45, CD58 and CD56 on
PPCs maintained their explicative power, so they are
good candidates for further studies, especially CD19,
which was considered a “reliable” antigen in a report
exploring relationship between MFC and histological
results (56). In conclusion, we have provided a feasible
start point to put in order the ranges of expression on
PPCs in healthy and myeloma subjects; we propose a
new approach based on analysis of PPCs to monitor the
stages of the disease. However, the study size is small,
and we could not provide a prospective cohort to exam-
ine fluctuations in expression of MFC markers related to
time and disease progression, just as we could not
define a threshold of expression for each marker that
allows to clearly attribute each subject to his own
group. Confirmation by larger and deeper independent
studies, as well as by the elaboration of an adequate
Cox proportional-hazard model, is indicated.
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